According to our research report, the size of the Biopsy Devices Market in Europe was worth USD 518.49 million in 2020 and estimated to be growing at a CAGR of 7.1% to reach USD 730.61 million by 2025. Europe holds the second primary market for biopsy devices owing to the acceptance of advanced technology in the biotechnology and research sector and innovation technologies.
Biopsy devices are attaining importance due to the rising incidence of cancer and the growing willingness of patients to spend money on these medical procedures. Biopsies are generally performed to recognize and diagnose if the tumor is cancerous and then design a suitable treatment plan.
The European market for biopsy devices is mainly driven by broader execution of national cancer screening programs, an increase in reimbursement coverage for biopsy processes, growing adoption of premium-priced devices, and favorable demographics. Low R&D expenses may boost the market share in emerging countries, an excessive pool of diseases and cancer populations points towards the rise in the market share of the emerging countries.
The increase in the number of cancer patients is driving the European biopsy devices market. European countries focus more on providing low cost and better-quality treatment options to the people along with the rapid adoption of medical devices, surgical centers, and the increasing awareness about the biopsy. It is boosting the European biopsy device market's growth. EU WHO develop programs for cancer control also coordinate & research on cause with strategic developments. Growth in the diagnostic centers, the better infrastructure of hospital facilities, and involvement in the R & D sector expand the biopsy devices market in the European region. The European government has started the CANCER-ID project. The project team focused on four mainstream through liquid biopsy testing for cancer. This project, funded by public partnerships between the Europe union & Europe pharmaceutical industry, is covered by 38 industry partners from 13 European countries. This project may lead to the growth of the European biopsy devices market. Around 60% of coeliac disease patients have been diagnosed by without biopsy.
This research report has been segmented & sub-segmented into the following categories:
Regionally, Germany is leading the biopsy devices market in the European region. German researcher develops a liquid biopsy test for skin cancer detection, and the new technique makes screening faster for cancer patients. Germany has its own regulatory body, i.e., the Federal Joint Committee and all decisions regarding any healthcare drugs & medical devices taken by the committee. Germany is the largest medical device market, adopting the MRI, X-RAY guide the practitioner, physicians for biopsy. Germany, Agena Biosciences Company, is exploring the new technical biopsy devices in the market. German companies manufacture advanced biopsy devices over the world with higher efficiency in less time.
The European mammography division of GE Healthcare has performed first breast cancer Angio- mammography by using Pristina Serena biopsy robot on a patient. U.S. Food & Drug Administration gives clearance to Pristina Serena Bright™ for the treatment. France provides a large no. of skilled medical professionals for the biopsy; it gains market value towards the growth.
Germany is leading the biopsy devices market in the European region. The country develops its research, which acts as a liquid biopsy test for detecting skin cancer, making quick and easy screening for patients. A growing number of cancer cases as cancer has become one of the most leading causes of death across the globe. In 2012, the occurrence rate of cancer was 14.1million and was estimated to grow up to 70.0% over the next 20years.
In Spain, the biopsy devices market is expected to have strong growth over the upcoming years due to growing frequent occurring rare diseases like cancer, and others. In 2018, there were about nearly 270 363 cases of cancer, and 113,584 deaths took place due to cancer.
UK is expected to hold the second-largest share in the biopsy devices market over the European region due to the increase of various cancers like prostate, breast, lung, colon, and skin, which are the most common types found in the UK. In 2018, nearly 446,942 new cancer cases were recorded in the UK.
In France, the cancer occurrence rate has been increased from 1990 to 2018. In 1990, there were about 215,000 cancer cases and has been escalated to 382,000 by 2018, which is estimated to drive growth for the biopsy devices market in France.
Companies playing an essential role in the biopsy devices market in Europe region profiled in this report are Medtronic, Leica Biosystems, Hologic Inc., Boston Scientific Corporation, Becton, Cook Medical Inc., C.R. Bard Inc., Mauna Kea Technologies, Ethicon EndoSurgery Inc., Veran Medical Technologies, Dickinson and Company, Fujifilm Medical Systems, MDxHealth, Argon Medical Devices Inc and Intact Medical Corp.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1.4 Y-o-Y Growth Analysis, By Product
5.1.5 Market Attractiveness Analysis, By Product
5.1.6 Market Share Analysis, By Product
5.2.2 Needle Biopsy
18.104.22.168 Core Needle Biopsy
22.214.171.124 Fine Needle Biopsy
126.96.36.199 Vacuum-Assisted Biopsy
5.2.3 Surgical Biopsy
188.8.131.52 Incisional Biopsy
184.108.40.206 Excisional Biopsy
5.2.5 Y-o-Y Growth Analysis, By Type
5.2.6 Market Attractiveness Analysis, By Type
5.2.7 Market Share Analysis, By Type
5.3.2 Scientific Research
5.3.3 Medical Diagnosis
5.3.4 Agricultural Applications
5.3.5 Genetic fingerprinting & Sex Determination
5.3.6 Y-o-Y Growth Analysis, By Application
5.3.7 Market Attractiveness Analysis, By Application
5.3.8 Market Share Analysis, By Application
5.4 End Users
5.4.2 Pharmaceutical and Biotechnology Industry
5.4.3 Academic Research Institute
5.4.4 Contract Research Organizations
5.4.5 Forensic Labs
5.4.6 Y-o-Y Growth Analysis, By End Users
5.4.7 Market Attractiveness Analysis, By End Users
5.4.8 Market Share Analysis, By End Users
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
220.127.116.11 By Geographical Area
18.104.22.168 By Product
22.214.171.124 By Type
126.96.36.199 By Application
188.8.131.52 By End User
6.1.4 Market Attractiveness Analysis
184.108.40.206 By Geographical Area
220.127.116.11 By Product
18.104.22.168 By Type
22.214.171.124 By Application
126.96.36.199 By End User
6.1.5 Market Share Analysis
188.8.131.52 By Geographical Area
184.108.40.206 By Product
220.127.116.11 By Type
18.104.22.168 By Application
22.214.171.124 By End User
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Leica Biosystems
8.3 Hologic Inc.
8.4 Boston Scientific Corporation
8.6 Cook Medical Inc.
8.7 C.R. Bard Inc.
8.8 Mauna Kea Technologies
8.9 Ethicon EndoSurgery Inc.
8.10 Veran Medical Technologies
8.11 Dickinson and Company
8.12 Fujifilm Medical Systems
8.14 Argon Medical Devices Inc
8.15 Intact Medical Corp
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures